FILE 'REGISTRY' ENTERED AT 12:07:25 ON 24 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUL 2007 HIGHEST RN 943188-87-2 DICTIONARY FILE UPDATES: 23 JUL 2007 HIGHEST RN 943188-87-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L1 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 15
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE L2 STR

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 18
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE L3 STR

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
. L4 STR

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L5 (132) SEA FILE=REGISTRY SSS FUL L3 OR L4

L6 77 SEA FILE=REGISTRY SUB=L5 SSS FUL (L1 OR L2)

100.0% PROCESSED 132 ITERATIONS 77 ANSWERS

SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 12:07:25 ON 24 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jul 2007 VOL 147 ISS 5 FILE LAST UPDATED: 23 Jul 2007 (20070723/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

L7 5 S L6

E1 THROUGH E72 ASSIGNED

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 27 Sep 2006

ACCESSION NUMBER: 2006:1001119 CAPLUS Full-text

DOCUMENT NUMBER: 146:213

TITLE: Pyridone derivatives as potent, orally

bioavailable VLA-4 integrin antagonists

AUTHOR(S): Witherington, Jason; Blaney, Emma L.; Bordas,

Vincent; Elliott, Richard L.; Gaiba, Alessandra;

Garton, Neil; Green, Philip M.; Naylor,

Antoinette; Smith, David G.; Spalding, David J.;

Takle, Andrew K.; Ward, Robert W.

CORPORATE SOURCE: Department of DMPK and Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5538-5541 CODEN: BMCLE8; ISSN: 0960-894X PUBLISHER: Elsevier Ltd. DOCUMENT TYPE: Journal LANGUAGE: English OTHER SOURCE(S): CASREACT 146:213 A series of pyridone-N-benzylpropanoic acids have been optimized to afford potent orally bioavailable VLA-4 antagonists. 915157-68-5 915157-69-6 915157-70-9 IT 915157-71-0 915157-72-1 915157-73-2 915157-74-3 915157-75-4 915157-76-5 RL: PAC (Pharmacological activity); BIOL (Biological study) (optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists) ΙT 660439-96-3 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study) (optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists) ΙΤ 660439-93-0P 660440-22-2P 660440-23-3P 915157-77-6P 915157-78-7P 915157-79-8P 915157-80-1P 915157-81-2P 915157-82-3P 915157-83-4P 915157-84-5P 915157-85-6P 915157-86-7P 915157-87-8P 915157-88-9P 915157-89-0P 915157-90-3P 915157-91-4P 915157-93-6P RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists) REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN EDEntered STN: 16 May 2006 2006:453930 CAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 144:480470 TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists. [Erratum to document cited in CA144:403837] AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W. CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited Harlow, Essex, CM19 5AW, UK SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3341 CODEN: BMCLE8; ISSN: 0960-894X PUBLISHER: Elsevier B.V. DOCUMENT TYPE: Journal. LANGUAGE: English

AB The legends to Figures 1b and 3b are incorrect. In Figure 1b, the legend should read: "GASP molecular overlay of 8 (green) and 5 (yellow)". In Figure 3b, the legend should read: "Molecular overlay of 8 (green) and 10 (yellow)".

ΙT 660439-93-0P 660439-96-3P 660439-99-6P 660440-62-0P 884347-98-2P 884347-99-3P 884348-00-9P

> RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(pyridone derivs. as potent and selective VLA-4 integrin antagonists (Erratum))

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 16 Mar 2006

ACCESSION NUMBER: 2006:232883 CAPLUS Full-text

DOCUMENT NUMBER:

144:403837

TITLE:

Pyridone derivatives as potent and selective VLA-4

integrin antagonists

AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba,

> Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.;

Ward, Robert W.

CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI

Centre of Excellence for Drug Discovery,

GlaxoSmithKline Research Limited, Essex, CM19 5AW,

UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),

16(8), 2256-2259

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE:

Journal English LANGUAGE:

OTHER SOURCE(S): CASREACT 144:403837

GI

Ι

A novel series of pyridone inhibitors has been identified through AB pharmacophore anal., as potent antagonists of VLA-4. Analog I exhibited excellent inhibitory potency.

TΤ 660439-93-0P 660439-96-3P 660439-99-6P 660440-62-0P 884347-98-2P 884347-99-3P 884348-00-9P

> RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

```
(Uses)
```

(pyridone derivs. as potent and selective VLA-4 integrinantagonists)

REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

Entered STN: 23 Sep 2005 ED

ACCESSION NUMBER:

2005:1025806 CAPLUS Full-text

DOCUMENT NUMBER:

143:299147

TITLE:

Medicine compositions containing pyridone analogs

for inhibiting $\alpha 4$ -integrin-mediated cell

INVENTOR(S):

Witherington, Jason; Elliott, Richard Leonard

PATENT ASSIGNEE(S):

Tanabe Seiyaku Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 36 pp.

DOCUMENT TYPE:

CODEN: JKXXAF Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005255675	Α	20050922	JP 2005-33237	20050209
PRIORITY APPLN. INFO.:			JP 2004-31901 A	20040209

OTHER SOURCE(S):

MARPAT 143:299147

Medicine compns. containing pyridone analogs and their pharmacol. acceptable salts are claimed for inhibiting $\alpha 4$ -integrin-mediated cell adhesion for treatment of related diseases, including chronic inflammatory diseases, asthma, allergy, inflammatory bowel disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, organ transplant rejection, cardiovascular disease, diabetes, tumor, central nervous system diseases, etc.

```
TΤ
     660439-93-0P 660439-94-1P 660439-95-2P
     660439-96-3P 660439-97-4P 660439-98-5P
     660439-99-6P 660440-00-6P 660440-01-7P
     660440-02-8P 660440-03-9P 660440-05-1P
```

660440-07-3P 660440-12-0P 660440-13-1P 660440-14-2P 660440-15-3P 660440-16-4P

660440-17-5P 660440-18-6P 660440-19-7P

660440-20-0P 660440-21-1P 660440-22-2P 660440-23-3P 660440-24-4P 660440-25-5P

660440-26-6P 660440-27-7P 660440-28-8P

660440-29-9P 660440-30-2P 660440-31-3P

660440-32-4P 660440-33-5P 660440-34-6P

660440-35-7P 660440-36-8P 660440-37-9P

660440-38-0P 660440-39-1P 660440-40-4P

660440-41-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(medicine compns. containing pyridone analogs for inhibiting α4-integrin-mediated cell adhesion and treating related diseases)

- T.7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
- Entered STN: 22 Feb 2004 ED

ACCESSION NUMBER: 2004:143107 CAPLUS Full-text

DOCUMENT NUMBER: 140:199207

TITLE: Preparation of pyridones as inhibitors of $\alpha 4$

integrin-mediated cell adhesion.

INVENTOR(S): Witherington, Jason; Elliott, Richard Leonard

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.				KIND DATE		APPLICATION NO.						DATE				
						A2 20040219 A3 20040415			WO 2003-JP10119						20030808		
							AU,		BA.	BB.	BG.	BR.	BY.	BZ.	CA.	CH.	
•							DE,										
		•	•	•	•	•	ID,	•	•	•	•	•	•	•		•	
			•	•		•	LU,	•	•	•		•	•	•	•	•	
					•		PH,			•	•	•	•	•	•	•	
							TR,	•			•					•	
			ZM,		,	,	,	,	,	,	,	,	· - ,	,	,	,	
	RW:	•			LS.	MW.	MZ,	SD.	SL.	SZ.	TZ.	UG.	ZM.	ZW.	AM.	AZ.	
			•	•	•	•	TJ,	•	•	•	•	,	•	•	•	•	
		-				•	GR,		•	•	•	•	•	•	•	•	
				•	•	•	CF,	•	•	•	•	•	•	•	•	•	
		•	SN,	•	•	,	,	,	,	,	J. 1,	J.,	~ £ /		,	,	
CA	2493	•	•	,			2004	0219		CA 2	003-	2493	660		2	0030808	
	2003				A1		2004	0225		AU 2	003-	2560	69		2	0030808	
EP	1539	696			A2	-	2005									0030808	
	R:	AT.	BE.	CH.	DE.	DK.	ES,									MC.	
																HU, SK	
CN	1688			•			2005			CN 2						0030808	
JP	2005	5357	02		Т		2005	1124								0030808	
US	2005	2883	37													0050209	
PRIORIT																0020810	
										WO 2	003-	JP10	119	,	W 2	8080800	

OTHER SOURCE(S):

MARPAT 140:199207

GI

$$(R1)_{m} = Q \qquad V \qquad (R2)_{n} \qquad X = Y = Z \qquad (R3)_{p} \qquad (CH2)_{q} = W \qquad NH \qquad L-B < (R3)_{p} \qquad (CH2)_{q} = W \qquad (R3)_{p} \qquad ($$

Title compds. [I; A, B = aryl, heteroaryl; Q = C, CH; QV, QD = 5-7 membered heterocyclyl; D = H, alkyl; R1-R3 = alkyl, halo, alkoxy, OH, cyano, CF3, NO2, alkylthio, amino, CO2H, alkanoyl, amido, NHCOR9, NHSO2R9; R9 = alkyl, cycloalkyl, (substituted) Ph etc.; R4 = H, alkyl, halo, alkoxy; V = O, S, amino, NNO2, NCN; W, X, Y, Z = C, CH, CH2; dotted line = single or double

```
bond; L = (CH2)r, (CH2)rrO; r = 0-3; rr = 2, 3; J = CR5:CR6, CHR7CHR8, single
     bond, CHR6; OCHR10, etc.; R5, R6, R10 = H, alkyl; R7, R8 = H, alkyl,
     cycloalkyl, aryl, heteroaryl, etc.; m, n, p = 0-3; q = 0-2], were prepared as
     inhibitors of \alpha 4 integrin-mediated cell adhesion (no data). Thus, Et 3-[4-[2-
     oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1- ylmethyl]phenyl]propionate and
     LiOH were stirred at 60^{\circ} for 30 min in THF/H2O to give after acidification
     with HCl 3-[3-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1-
     ylmethyl]phenyl]propionic acid.
ΙT
     660439-93-0P 660439-94-1P 660439-95-2P
     660439-96-3P 660439-97-4P 660439-98-5P
     660439-99-6P 660440-00-6P 660440-01-7P
     660440-02-8P 660440-03-9P 660440-05-1P
     660440-07-3P 660440-12-0P 660440-13-1P
     660440-14-2P 660440-15-3P 660440-16-4P
     660440-17-5P 660440-18-6P 660440-19-7P
     660440-20-0P 660440-21-1P 660440-22-2P
     660440-23-3P 660440-24-4P 660440-25-5P
     660440-26-6P 660440-27-7P 660440-28-8P
     660440-29-9P 660440-30-2P 660440-31-3P
     660440-32-4P 660440-33-5P 660440-34-6P
     660440-35-7P 660440-36-8P 660440-37-9P
     660440-38-0P 660440-39-1P 660440-40-4P
     660440-41-5P 660440-62-0P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of pyridones as inhibitors of \alpha 4 integrin-mediated
        cell adhesion)
     FILE 'REGISTRY' ENTERED AT 12:09:19 ON 24 JUL 2007
             72 SEA FILE=REGISTRY ABB=ON PLU=ON
L8
                                                  (660439-93-0/BI OR
                660439-96-3/BI OR 660439-99-6/BI OR 660440-22-2/BI OR
                660440-23-3/BI OR 660440-62-0/BI OR 660439-94-1/BI OR
                660439-95-2/BI OR 660439-97-4/BI OR 660439-98-5/BI OR
                660440-00-6/BI OR 660440-01-7/BI OR 660440-02-8/BI OR
                660440-03-9/BI OR 660440-05-1/BI OR 660440-07-3/BI OR
                660440-12-0/BI OR 660440-13-1/BI OR 660440-14-2/BI OR
                660440-15-3/BI OR 660440-16-4/BI OR 660440-17-5/BI OR
                660440-18-6/BI OR 660440-19-7/BI OR 660440-20-0/BI OR
                660440-21-1/BI OR 660440-24-4/BI OR 660440-25-5/BI OR
                660440-26-6/BI OR 660440-27-7/BI OR 660440-28-8/BI OR
                660440-29-9/BI OR 660440-30-2/BI OR 660440-31-3/BI OR
                660440-32-4/BI OR 660440-33-5/BI OR 660440-34-6/BI OR
                660440-35-7/BI OR 660440-36-8/BI OR 660440-37-9/BI OR
                660440-38-0/BI OR 660440-39-1/BI OR 660440-40-4/BI OR
                660440-41-5/BI OR 884347-98-2/BI OR 884347-99-3/BI OR
                884348-00-9/BI OR 915157-68-5/BI OR 915157-69-6/BI OR
                915157-70-9/BI OR 915157-71-0/BI OR 915157-72-1/BI OR
                915157-73-2/BI OR 915157-74-3/BI OR 915157-75-4/BI OR
                915157-76-5/BI OR 915157-77-6/BI OR 915157-78-7/BI OR
                915157-79-8/BI OR 915157-80-1/BI OR 915157-81-2/BI OR
                915157-82-3/BI OR 915157-83-4/BI OR 915157-84-5/BI OR
```

915157-85-6/BI OR 915157-86-7/BI OR 915157-87-8/BI OR 915157-88-9/BI OR 915157-89-0/BI OR 915157-90-3/BI OR

=> d 1,5,9,18,26,27,29,35,42,58,66,72 ide can

L8 ANSWER 1 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN RN 915157-93-6 REGISTRY

915157-91-4/BI OR 915157-93-6/BI)

ED Entered STN: 11 Dec 2006

CN Benzenepropanoic acid, β -methyl-4-[[3-[2-methyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (β S)- (CA INDEX NAME)

FS STEREOSEARCH

MF C31 H31 N3 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 5 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN **915157-88-9** REGISTRY

ED Entered STN: 11 Dec 2006

CN Benzenepropanoic acid, $4-[[3-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-<math>\beta$ -methyl-, (β S)- (CA INDEX NAME)

FS STEREOSEARCH

MF C32 H33 N3 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 9 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN **915157-84-5** REGISTRY

ED Entered STN: 11 Dec 2006

CN Benzenepropanoic acid, $4-[[3-[2-chloro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-<math>\beta$ -methyl-, (β R)- (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H28 C1 N3 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 18 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN **915157-75-4** REGISTRY

ED Entered STN: 11 Dec 2006

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2,5-dimethylphenyl)amino]carbonyl] amino]-3-methoxyphenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)

MF C31 H31 N3 O5

SR CA

LC STN Files: CA, CAPLUS

$$HO_2C-CH_2-CH_2$$
 CH_2
 NH
 NH
 NH
 NH
 NH
 NH
 NH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 26 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN 884348-00-9 REGISTRY

ED Entered STN: 15 May 2006

CN Benzeneacetic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

MF C28 H25 N3 O4

SR CA

LC STN Files: CA, CAPLUS

$$\mathsf{HO_2C-CH_2} \qquad \qquad \mathsf{NH-C-NH}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

L8 ANSWER 27 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN **884347-99-3** REGISTRY

ED Entered STN: 15 May 2006

CN Benzenepropanoic acid, 2-[[3-[4-[[(2-methylphenyl)amino]carbonyl]amin o]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

MF C29 H27 N3 O4

SR CA.

LC STN Files: CA, CAPLUS

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES 'IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

L8 ANSWER 29 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN 660440-62-0 REGISTRY

ED Entered STN: 09 Mar 2004

CN Benzenepropanoic acid, 3-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amin o]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

MF C29 H27 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

$$HO_2C = CH_2 = CH_2$$
 $CH_2 = CH_2$
 $NH = C$
 N

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

REFERENCE 3: 140:199207

L8 ANSWER 35 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN 660440-36-8 REGISTRY

ED Entered STN: 09 Mar 2004

CN Benzenepropanoic acid, 3-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amin o]phenyl]-2-oxo-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

MF C29 H31 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:299147

REFERENCE 2: 140:199207

L8 ANSWER 42 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN 660440-29-9 REGISTRY


ED Entered STN: 09 Mar 2004

CN Benzenepropanoic acid, 4-[[3-[4-[[(2,3-dihydro-1H-indol-1-yl)carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

MF C30 H27 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:299147

REFERENCE 2: 140:199207

L8 ANSWER 58 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN 660440-13-1 REGISTRY


ED Entered STN: 09 Mar 2004

CN Benzeneacetic acid, 4-[2-[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

MF C29 H27 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:299147

REFERENCE 2: 140:199207

L8 ANSWER 66 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN **660439-99-6** REGISTRY

ED Entered STN: 09 Mar 2004

CN Benzoic acid, 4-[[3-[4-[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

MF C27 H23 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

REFERENCE 3: 143:299147

REFERENCE 4: 140:199207

L8 ANSWER 72 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN

RN 660439-93-0 REGISTRY


ED Entered STN: 09 Mar 2004

CN Benzenepropanoic acid, 4-[[3-[4-[[(2-methylphenyl)amino]carbonyl]amin o]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)

MF C29 H27 N3 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

REFERENCE 2: 144:480470

REFERENCE 3: 144:403837

REFERENCE 4: 143:299147

REFERENCE 5: 140:199207

FILE 'CAOLD' ENTERED AT 12:11:20 ON 24 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L9 . 0 L6

FILE 'MEDLINE' ENTERED AT 12:11:29 ON 24 JUL 2007

FILE 'BIOSIS' ENTERED AT 12:11:29 ON 24 JUL 2007 Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:11:29 ON 24 JUL 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

L10 0 L6

=> fil hom FILE 'HOME' ENTERED AT 12:11:39 ON 24 JUL 2007

FILE 'CAPLUS' ENTERED AT 15:13:07 ON 20 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:13:07 ON 20 JUL 2007

FILE 'BIOSIS' ENTERED AT 15:13:07 ON 20 JUL 2007 Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:13:07 ON 20 JUL 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIX' ENTERED AT 15:13:07 ON 20 JUL 2007 COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'JAPIO' ENTERED AT 15:13:07 ON 20 JUL 2007 COPYRIGHT (C) 2007 Japanese Patent Office (JPO) - JAPIO

FILE 'PASCAL' ENTERED AT 15:13:07 ON 20 JUL 2007 Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'DISSABS' ENTERED AT 15:13:07 ON 20 JUL 2007 COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Res erved.

L15	205	SEA ABB=ON PLU=ON	"WITHERINGTON J"?/AU
L16	6337	SEA ABB=ON PLU=ON	"ELLIOTT R"?/AU
L17	12	SEA ABB=ON PLU=ON	L15 AND L16
L18	24	SEA ABB=ON PLU=ON	(L15 OR L16) AND ((ALPHA4 OR A4 OR (A .
		OR ALPHA) (W) 4) (3A	A) INTEGRIN OR (CD49? OR CD 49)(5A)
		ANTIGEN OR (CELL C	R CELLULAR) (3A) ADHESION)
L19	30	SEA ABB=ON PLU=ON	L17 OR L18
L20	16	DUP REM L19 (14 DU	PLICATES REMOVED)

L20 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

ACCESSION NUMBER:

2007:33257 CAPLUS Full-text

DOCUMENT NUMBER:

146:142654

TITLE:

Preparation of imidazopyridines as acid pump

antagonists.

INVENTOR(S):

Bamford, Mark James; Elliott, Richard

Leonard; Giblin, Gerard Martin Paul; Naylor, Antoinette; Panchal, Terence Aaron; Takle, Andrew

Kenneth; Witherington, Jason

PATENT ASSIGNEE(S): SOURCE:

Glaxo Group Limited, UK PCT Int. Appl., 40pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DA	ATE APPI	LICATION NO.	DATE
WO 2007003386	A1 20	0070111 WO 2	2006-EP6410	20060628
W: AE, AG, AL,	AM, AT, A	AU, AZ, BA, BB,	BG, BR, BW, BY	, BZ, CA,
CH, CN, CO,	CR, CU, C	CZ, DE, DK, DM,	DZ, EC, EE, EG	, ES, FI,

```
GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO::

GB 2005-13423

A 20050630
```

OTHER SOURCE(S):

MARPAT 146:142654

GI

$$\begin{array}{c|c}
Y & R1 \\
\hline
R3 & X \\
R4 & R5
\end{array}$$

Ι

AB Title compds. [I; X = NH, NR7, O; R1 = H, alkyl, CH2CN, CH2NH2, cycloalkyl, alkenyl, alkynyl, fluoroalkyl, alkylsulfonylalkyl, amino, etc.; R2 = alkyl, amino, cycloalkyl, cycloalkylalkyl, alkoxy, alkenyl, hydroxyalkyl, cyanoalkyl, haloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl, OH, halo, amino, alkoxy; R3R4 = atoms to form (substituted) 5-6 membered heterocyclic ring; R6 = H, alkyl, halo, OH, amino, alkoxycarbonylamino; R7 = alkyl; R4R7 = atoms to form (substituted) 5-7 membered heterocyclyl; Y = (substituted) 4-7 membered nonarom. heterocyclyl], were prepared Thus, 6-bromo-N-[(2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine, 2-pyrrolidinone, tris(dibenzylidineacetone)dipalladium, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthine, and Cs2CO3 were refluxed together in dioxane to give 1-[8-[[(2,6-dimethylphenyl)methyl]amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-2-pyrrolidinone hydrochloride. I inhibited H+/K+ ATPase at <5 μM.

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER:

2007:281174 CAPLUS Full-text

DOCUMENT NUMBER:

146:330828

3

TITLE:

Pharmaceutical compositions containing .

alpha.-4 integrin
mediated cell adhesion

inhibitors

INVENTOR(S):

Ward, Robert William; Witherington, Jason

PATENT ASSIGNEE(S):

Tanabe Seiyaku Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 38pp.

CODEN: JKXXAF

DOCUMENT TYPE:

LANGUAGE:

Patent Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063268	A	20070315	JP 2006-212923	20060804
PRIORITY APPLN. INFO.:			JP 2005-227980 A	20050805

OTHER SOURCE(S):

MARPAT 146:330828

GΙ

$$(R1)_{m} \xrightarrow{H} (R2)_{n}$$

$$(R1)_{m} \xrightarrow{R4'} \xrightarrow{R4'} \xrightarrow{R4} L \xrightarrow{(R3)_{p}} L \xrightarrow{(R3)_{p}} L \xrightarrow{CO_{2}H} L$$

AΒ The invention relates to a pharmaceutical composition characterized by containing a compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di-)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di-)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least on of X, Y, and Z is N; $L = -(CH2)q^{-}$, $-(CH2)q^{'}O^{-}$, wherein q = 0=3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against $\alpha-4$ integrin mediated cell adhesion, and is suitable for use for treatment of α -4 integrin mediated cell adhesion-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o- tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.

L20 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3

ACCESSION NUMBER:

2007:613414 CAPLUS Full-text

TITLE:

SOURCE:

Therapeutic approaches towards the treatment of

gastrointestinal disorders

AUTHOR(S):

Collingwood, Steve; Witherington, Jason

CORPORATE SOURCE:

Drug News & Perspectives (2007), 20(2), 139-144

CODEN: DNPEED; ISSN: 0214-0934

PUBLISHER:

Prous Science

DOCUMENT TYPE:

Journal; General Review

LANGUAGE:

English ·

A review. The Society for Medicines Research gathered an international panel AB of speakers and about 60 delegates for their symposium Sept. 21, 2006, on

Therapeutic Approaches Towards the Treatment of Gastrointestinal Disorders, at the National Heart and Lung Institute, in London, U.K. The focus of the conference was to discuss therapeutic strategies taken towards the treatment of inflammatory bowel disease, acid-related disorders and irritable bowel syndrome. Key note lectures addressed the development of tegaserod, a 5-HT4 receptor agonist, for the treatment of constipation dominant irritable bowel syndrome (cIBS), the use of tumor necrosis factor α (TNF α) inhibitors in the treatment of chronic inflammatory disease, including Crohn's disease, the development of effective inhibitors of gastric acid secretion, the role of alpha.4.beta.7 integrin in the development of Crohn's disease and ulcerative colitis, the parts played by the neuropeptides ghrelin and motilin in the control of gastrointestinal motility, and the role of bacteria in functional gastrointestinal disease.

L20 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2006:1006666 CAPLUS Full-text

DOCUMENT NUMBER:

145:377339

TITLE:

Preparation of imidazo[1,2-a]pyridine derivatives

useful as medicaments for treating

gastrointestinal diseases

INVENTOR(S):

Bamford, Mark James; Elliott, Richard

Leonard; Giblin, Gerard Martin Paul; Naylor,

Antoinette; Witherington, Jason;

Panchal, Terence Aaron; Demont, Emmanuel Hubert

PATENT ASSIGNEE(S):

SOURCE:

Glaxo Group Limited, UK PCT Int. Appl., 128pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.					KIND DATE			APPLICATION NO.						DATE				
	WO	2006	1001	19		A1	-	2006	 0928	,	 WO 2	006-	EP29	52		2	0060322	
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	
			CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	
			GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	
								LK,										
			MK,	MN,	MW,	$MX_{!}$	ΜZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	
	•		RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	
								VC,									•	
		RW:						CZ,										
								LV,										
								CM,										
								LS,					SL,	SZ,	TZ,	UG,	ZM,	
						BY,	KG,	ΚZ,	MD,									
PRIOF	RITY	APP]	LN.	INFO	. :						GB 2	005-	6137			A 2	0050324	
										(GB 2	005-	7101			A 2	0050407	
								•		•	GB 2	005-	1292	3		A 2	0050624	
										(GB 2	005-	2127	4		A 2	0051019	

OTHER SOURCE(S):

MARPAT 145:377339

GΙ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = NH, N-alkyl, O; R1 = H, cyclo/alkyl, alkoxy, NH2 andderivs., etc.; R2 = cyclo/halo/alkyl, NH2, etc.; R3 = H, alkyl; R4, R5 = independently H, alkyl, OH, halo, alkoxy, NH2 and derivs.; or R3CCCR4 = (un) substituted 5- to 6-membered carbocyclyl or heterocyclyl; R6 = H, alkyl, halo, OH, NHCO2-alkyl, NH2 and derivs.; Ar = (un)substituted aryl, 5- to 6membered monocyclyl or 7- to 12-membered bicyclyl heteroaryl; and their pharmaceutically acceptable salts; with the exception of one specified compound] were prepared for treating diseases or disorders where an acid pump antagonist is required such as gastrointestinal diseases associated with an imbalance in gastric acid (no data). Thus, cyclization of 2-amino-3,5dibromopyridine with 3-bromo-2-butanone, reaction of the dibromide with (2,6dimethylphenyl)methanol, and Pd-coupling of the bromide with phenylboronic acid gave imidazopyridine II. Selected I were tested in H+/K+-ATPase activity assays.

REFERENCE COUNT:

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4

ACCESSION NUMBER:

2006:1001119 CAPLUS Full-text

DOCUMENT NUMBER:

146:213

TITLE:

AUTHOR(S):

Pyridone derivatives as potent, orally

bioavailable VLA-4 integrin antagonists Witherington, Jason; Blaney, Emma L.;

Bordas, Vincent; Elliott, Richard L.;

Gaiba, Alessandra; Garton, Neil; Green, Philip M.; Naylor, Antoinette; Smith, David G.; Spalding,

David J.; Takle, Andrew K.; Ward, Robert W.

CORPORATE SOURCE: Department of DMPK and Medicinal Chemistry,

Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited,

Essex, CM19 5AW, UK

SOURCE:

Bioorganic & Medicinal Chemistry Letters (2006),

16(21), 5538-5541

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER:

Elsevier Ltd.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 146:213

A series of pyridone-N-benzylpropanoic acids have been optimized to afford potent orally bioavailable VLA-4 antagonists.

REFERENCE COUNT:

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L20 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN 2006:453930 CAPLUS Full-text

ACCESSION NUMBER:

144:480470

DOCUMENT NUMBER: TITLE:

Pyridone derivatives as potent and selective VLA-4 integrin antagonists. [Erratum to document cited

AUTHOR(S):

in CA144:403837] Witherington, Jason; Bordas, Vincent;

Gaiba, Alessandra; Green, Phil M.; Naylor,

Antoinette; Parr, Nigel; Smith, David G.; Takle,

Andrew K.; Ward, Robert W.

CORPORATE SOURCE:

Department of Medicinal Chemistry, Neurology & GI

Centre of Excellence for Drug Discovery,

GlaxoSmithKline Research Limited Harlow, Essex,

CM19 5AW, UK

SOURCE:

Bioorganic & Medicinal Chemistry Letters (2006),

16(12), 3341

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER:

Elsevier B.V.

DOCUMENT TYPE:

Journal

LANGUAGE: English

The legends to Figures 1b and 3b are incorrect. In Figure 1b, the legend should read: "GASP molecular overlay of 8 (green) and 5 (yellow)". In Figure 3b, the legend should read: "Molecular overlay of 8 (green) and 10 (yellow)".

L20 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5

ACCESSION NUMBER:

2006:232883 CAPLUS Full-text

DOCUMENT NUMBER:

144:403837

TITLE:

Pyridone derivatives as potent and selective VLA-4

integrin antagonists

AUTHOR(S):

Witherington, Jason; Bordas, Vincent;

Gaiba, Alessandra; Green, Phil M.; Naylor,

Antoinette; Parr, Nigel; Smith, David G.; Takle,

Andrew K.; Ward, Robert W.

CORPORATE SOURCE:

Department of Medicinal Chemistry, Neurology & GI

Centre of Excellence for Drug Discovery,

GlaxoSmithKline Research Limited, Essex, CM19 5AW,

SOURCE:

Bioorganic & Medicinal Chemistry Letters (2006),

16(8), 2256-2259

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER:

Elsevier B.V.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 144:403837

GΙ

AΒ A novel series of pyridone inhibitors has been identified through pharmacophore anal., as potent antagonists of VLA-4. Analog I exhibited excellent inhibitory potency.

REFERENCE COUNT:

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 8 OF 16 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on L20 STN

10/524028 2007:187178 BIOSIS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: PREV200700193313 TITLE: Copper homeostasis: use of in vitro cell systems and transcriptional analysis to detect markers of copper regulation in human subjects. AUTHOR(S): Wortley, G. M. [Reprint Author]; Elliott, R. M. ; Harvey, L. J.; Fairweath-Tait, S. J. CORPORATE SOURCE: Hong Kong Polytech Univ, Fac Hlth and Social Sci, Kowloon, Hong Kong, Peoples R China SOURCE: Proceedings of the Nutrition Society, (2006) Vol. 65, No. Suppl. S, pp. 103A. Meeting Info.: Meeting on Interactions Between Genetics, Diet, Health and Disease. Aberdeen, UK. July 03 -06, 2006. CODEN: PNUSA4. ISSN: 0029-6651. DOCUMENT TYPE: Conference; (Meeting) Conference; Abstract; (Meeting Abstract) LANGUAGE: English ENTRY DATE: Entered STN: 14 Mar 2007 Last Updated on STN: 14 Mar 2007 L20 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 6 ACCESSION NUMBER: 2005:823674 CAPLUS Full-text DOCUMENT NUMBER: 143:229873 TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases INVENTOR(S): Ward, Robert William; Witherington, Jason PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan SOURCE: PCT Int. Appl., 58 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: 5.3 mm. 120

PATENT NO.						KIND DATE			APPLICATION NO.						DATE		
W	2005	0754	38		A1		2005	0818	1	WO 2	005-	JP21	94		2	0050208	
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	
		CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	
		GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	
		KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	
		MX,	MZ,	NΑ,	NI,	NO,	ΝZ,	OM,	PG,	PH,	PL,	PT,	RO,	ŖU,	SC,	SD,	
		SE,	SG,	SK,	SL,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	
		VC,	VN,	YU,	ZA,	ZM,	zw										
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	
		AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	
		DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	
		NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	
		GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG							
CA	1 2554	705			A1		2005	0818	(CA 2	005-2	2554	705		2	0050208	
E	? 1737	826			A1		2007	0103]	EP 2	005-	7101	95		20	0050208	
	R:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	
		IE,	IS,	ΙΤ,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR	
Ch	N 1918	133			Α		2007	0221	(CN 20	005-8	3000	4473		20	0050208	
PRIORIT	Y APP	LN.	INFO	.:					(GB 20	004-2	2812		Ā	A 20	0040209	

WO 2005-JP2194

W 20050208

OTHER SOURCE(S):

MARPAT 143:229873

GI

AB Title compds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1, R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O, S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least one X Y and Z is N; L = (CH2)q, (CH2)q'O; J = bond, CR5=CR6, CHR7CHR8, etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q' = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their pharmaceutically acceptable salts were prepared For example, saponification of Et ester II (G = OEt) afforded carboxylic acid II (G = OH). Compoounds I are claimed to be useful as alpha-4 integrin mediated cell

adhesion inhibitors (no data provided).

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 7

ACCESSION NUMBER:

2005:1025806 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER:

143:299147

TITLE:

Medicine compositions containing pyridone analogs

for inhibiting .alpha.4-integrin-mediated cell

adhesion

INVENTOR(S):

Witherington, Jason; Elliott,

Richard Leonard

PATENT ASSIGNEE(S):

Tanabe Seiyaku Co., Ltd., Japan Jpn. Kokai Tokkyo Koho, 36 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005255675	A	20050922	JP 2005-33237	20050209

PRIORITY APPLN. INFO.:

JP 2004-31901

A 20040209

OTHER SOURCE(S):

MARPAT 143:299147

AB Medicine compns. containing pyridone analogs and their pharmacol. acceptable salts are claimed for inhibiting .alpha.4 -integrin-mediated cell adhesion for treatment of related diseases, including chronic inflammatory diseases, asthma, allergy, inflammatory bowel disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, organ transplant rejection, cardiovascular disease, diabetes, tumor, central nervous system diseases, etc.

L20 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2005:1341075 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER:

144:271286

TITLE:

Expression and functional analysis of genes

deregulated in mouse placental overgrowth models:

Car2 and Ncam1

AUTHOR(S):

Singh, Umashankar; Sun, Tong; Shi, Wei; Schulz,
Ralph; Nuber, Ulrike A.; Varanou, Aikaterini;
Hemberger, Myriam C.; Elliott, Rosemary W.
; Ohta, Hiroshi; Wakayama, Teruhiko; Fundele,

Reinald

CORPORATE SOURCE:

Department of Development and Genetics,

Evolutionary Biology Center, Uppsala University,

Uppsala, Swed.

SOURCE:

Developmental Dynamics (2005), 234(4), 1034-1045

CODEN: DEDYEI; ISSN: 1058-8388

PUBLISHER:

Wiley-Liss, Inc.

DOCUMENT TYPE:

Journal English

LANGUAGE:

AΒ Different causes, such as maternal diabetes, cloning by nuclear transfer, interspecific hybridization, and deletion of some genes such as Esx1, Ip1, or Cdknlc, may underlie placental overgrowth. In a previous study, we carried out comparative gene expression anal. in three models of placental hyperplasias, cloning, interspecies hybridization (IHPD), and Esxl deletion. This study identified a large number of genes that exhibited differential expression between normal and enlarged placentas; however, it remained unclear how altered expression of any specific gene was related to any specific placental phenotype. In the present study, we focused on two genes, Car2 and Ncaml, which both exhibited increased expression in interspecies and cloned hyperplastic placentas. Apart from a detailed expression anal. of both genes during normal murine placentation, we also assessed morphol. of placentas that were null for Car2 or Ncam1. Finally, we attempted to rescue placental hyperplasia in a congenic model of IHPD by decreasing transcript levels of Car2 or Ncam1. In situ anal. showed that both genes are expressed mainly in the spongiotrophoblast, however, expression patterns exhibited significant variability during development. Contrary to expectations, homozygous deletion of either Car2 or Ncaml did not result in placental phenotypes. However, expression anal. of Car3 and Ncam2, which can take over the function of Car2 and Ncam1, resp., indicated a possible rescue mechanism, as Car3 and Ncam2 were expressed in spongiotrophoblast of Car2 and Ncam1 mutant placentas. On the other hand, downregulation of either Car2 or Ncam1 did not rescue any of the placental phenotypes of AT24 placentas, a congenic model for interspecies hybrid placentas. This strongly suggested that altered expression of Car2 and Ncam1 is a downstream event in placental hyperplasia.

REFERENCE COUNT:

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER:

2004:143107 CAPLUS Full-text

DOCUMENT NUMBER:

140:199207

TITLE:

Preparation of pyridones as inhibitors of .

alpha.4 integrin

-mediated cell adhesion.

INVENTOR(S):

Witherington, Jason; Elliott,

Richard Leonard

PATENT ASSIGNEE(S):

Tanabe Seiyaku Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND DATE			APPLICATION NO.						DATE				
		2004				A2 20040219 A3 20040415		,	WO 2	003-	JP10:	119		20030808			
		W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,
								DE,									
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR.	KZ.
			-		•	•	•	LU,	•	•	•	•	•	•		•	•
							-	PH,	•	•	•	•	•	•	•	•	•
			-		•			TR,	•		. ,	•	•	•		•	•
				ZM,	-	,	,	,	,	,	,	,	,	,	,	,	,
		RW:	•	•		LS.	MW.	MZ.	SD.	SL.	SZ.	TZ.	UG.	ZM.	ZW.	AM.	AZ.
			•	-				ТJ,			•	•		•		•	•
								GR,									
						•		CF,		•	•	•	•	•		•	•
			-	SN,	-		_,	/	00,	01,	0,	0,	0117	02/	J,	,	,
	CA	2493	•	•	•			2004	0219		CA 2	003-	2493	660		2	0030808
		2003				A1		2004									0030808
	EΡ	1539	696			A2		2005									0030808
								ES,									
,				•	•	•	,	•	•	. ,	- ,				. ,		HU, SK
	CN	1688	•	,	,	•	•	2005		•	•	•		•	•		0030808
	JР	2005	5357	02		Т		2005									0030808
		2005						2005									0050209
PRIO		Y APP															0020810
				•	-									-	•	_	
									•		WO 2	003-	JP10	119	1	w 2	0030808

OTHER SOURCE(S):

MARPAT 140:199207

GΙ

$$(R1)_{m} \xrightarrow{Q} \overset{V}{\text{N}} \xrightarrow{\text{N}} \overset{(R2)_{n}}{\text{N}} \xrightarrow{\text{CH}_{2}} \overset{Y}{\text{Q}} \xrightarrow{\text{N}} \overset{Z}{\text{N}} \overset{Z}{\text{N}} L - B \overset{(R3)_{p}}{\text{JCO}_{2}H}$$

Title compds. [I; A, B = aryl, heteroaryl; Q = C, CH; QV, QD = 5-7 membered AΒ heterocyclyl; D = H, alkyl; R1-R3 = alkyl, halo, alkoxy, OH, cyano, CF3, NO2, alkylthio, amino, CO2H, alkanoyl, amido, NHCOR9, NHSO2R9; R9 = alkyl, cycloalkyl, (substituted) Ph etc.; R4 = H, alkyl, halo, alkoxy; V = O, S,

amino, NNO2, NCN; W, X, Y, Z = C, CH, CH2; dotted line = single or double bond; L = (CH2)r, (CH2)rrO; r = 0-3; rr = 2, 3; J = CR5:CR6, CHR7CHR8, single bond, CHR6; OCHR10, etc.; R5, R6, R10 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, aryl, heteroaryl, etc.; m, n, p = 0-3; q = 0-2], were prepared as inhibitors of . alpha.4 integrin-mediated cell adhesion (no data). Thus, Et 3-[4-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1-ylmethyl]phenyl]propionate and LiOH were stirred at 60° for 30 min in THF/H2O to give after acidification with HCl <math>3-[3-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1-ylmethyl]phenyl]propionic acid.

L20 ANSWER 13 OF 16 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation

on STN

ACCESSION NUMBER:

2004:198917 BIOSIS Full-text

DOCUMENT NUMBER:

PREV200400199476

TITLE:

Microarray analysis reveals functional clustering of gene expression in dentate granule cells over extended

timecourses of development and epileptogenesis.

AUTHOR(S):

Elliott, R. C. [Reprint Author]; Otu, H.;

Kruegel, B. R. [Reprint Author]; Usta, F.; Libermann,

T.; Lowenstein, D. H.

CORPORATE SOURCE:

Neurol., Beth Israel Deaconess Med. Ctr., Boston, MA,

TSA

SOURCE:

Society for Neuroscience Abstract Viewer and Itinerary

Planner, (2003) Vol. 2003, pp. Abstract No. 411.1.

http://sfn.scholarone.com. e-file.

Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12,

2003. Society of Neuroscience.

DOCUMENT TYPE:

Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE:

English

ENTRY DATE:

Entered STN: 14 Apr 2004

Last Updated on STN: 14 Apr 2004

AB Prior findings in our laboratory support the concept that molecular mechanisms underlying aspects of dentate granule cell (DGC) development may play important roles in epilepsy-associated DGC plasticity. To define and compare patterns of DGC gene expression during development and epileptogenesis further, we have performed microarray analyses over the first 28 postnatal days of rat DGC development and the first 60 days following pilocarpineinduced status epilepticus (SE) in a rodent model of human temporal lobe epilepsy. Of the 8800 genes on the Affymetrix microarrays used, approximately 700 genes were found to be regulated at one or more of 5 developmental timepoints analyzed. Half this number, or roughly 350 genes, were found to be regulated during one or more of 5 timepoints following SE. Self-organizing map (SOM) analysis of these regulated genes indicates that those with similar gene product function often share similar temporal profiles of expression. For instance, six different genes involved in calcium homeostasis/signaling that were down-regulated during epileptogenesis were grouped in two similarlyshaped clusters, and nine different sequences representing Major Histocompatibility Complex (MHC) family members were up-regulated with one of two distinct patterns following SE. In addition, nearly 100 genes were regulated during both development and epileptogenesis. Two genes, coding for the cell adhesion molecules neurotrimin and LAMP, co-clustered in developmental and epileptogenesis profiles that were very similar to each other. These results provide additional evidence of a reiteration of developmental mechanisms during epileptogenesis.

ACCESSION NUMBER: 85225713 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 4004930

TITLE: Relationship of biochemical drug effects to their

antitumor activity--II. Diacridines and

membrane-related reactions.

AUTHOR: Elliott R E; Karadsheh N S; Kole J;

Canellakis E S

CONTRACT NUMBER: CA 28852 (NCI)

GM 03070 (NIGMS)

SOURCE: Biochemical pharmacology, (1985 Jun 15) Vol. 34, No.

12, pp. 2123-8.

Journal code: 0101032. ISSN: 0006-2952.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198507

ENTRY DATE: Entered STN: 20 Mar 1990

Last Updated on STN: 3 Feb 1997 Entered Medline: 10 Jul 1985

A method is presented that determines the degree of attachment of cancer cells to normal cells. This method may be useful in determining the extent to which treatment of normal cells (or of a tumor-bearing host) with a particular chemotherapeutic agent may affect the degree of attachment of cancer cells to the normal cells. The effects of several diacridines upon this process are described. In addition, we have determined the ability of individual diacridines to alter the permeability of P-388 cells; this effect has been related to their antitumor properties. In general, the most effective antitumor diacridines are those that cause minimal disruption of cell permeability. Conversely, diacridines that disrupt cell permeability tend to have poor antitumor properties. It is considered that the toxicity of these compounds may be a necessary consequence of the assays used for testing anticancer agents, and may not necessarily be related to their antitumor activity.

L20 ANSWER 15 OF 16 JAPIO (C) 2007 JPO on STN

ACCESSION NUMBER: 2007-063268 JAPIO Full-text

PATENT INFORMATION:

PATENT NO KIND DATE ERA MAIN IPC

JP 2007063268 A 20070315 Heisei

APPLICATION INFORMATION

STN FORMAT: JP 2006-212923 20060804
ORIGINAL: JP2006212923 Heisei

PRIORITY APPLN. INFO.: JP 2005-227980 20050805

SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined

Applications, Vol. 2007

AN 2007-063268 JAPIO Full-text

L20 ANSWER 16 OF 16 JAPIO (C) 2007 JPO on STN

ACCESSION NUMBER: 2005-255675 JAPIO Full-text

TITLE: PHARMACEUTICAL COMPOSITION

INVENTOR: WITHERINGTON JASON; ELLIOT RICHARD

LEONARD

PATENT ASSIGNEE(S): TANABE SEIYAKU CO LTD

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
			-	
JP 2005255675	Α	20.050922	Heisei	A61K031-4418

APPLICATION INFORMATION

2005-255675

ΑN

STN FORMAT: JP 2005-33237 20050209 ORIGINAL: JP2005033237 Heisei

PRIORITY APPLN. INFO.: JP 2004-31901 20040209 SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined

Applications, Vol. 2005

JAPIO Full-text AΒ PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition effectively suppressing or inhibiting α <SB>4</SB>-integrin- interposed cell adhesion and effective for preventing or treating chronic inflammatory diseases. SOLUTION: This pharmaceutical composition contains as active ingredient a compound of formula(I) having α <SB>4</SB>-integrin- interposed cell adhesion inhibitory activity or a pharmaceutically acceptable derivative thereof. COPYRIGHT: (C) 2005, JPO&NCIPI

FILE 'HOME' ENTERED AT 15:19:56 ON 20 JUL 2007

L1 STR

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 15
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE L2 STR

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 18
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE L3 STR

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED

STEREO ATTRIBUTES: NONE L4 STR

NUMBER OF NODES IS 17

VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L5 (132)SEA FILE=REGISTRY SSS FUL L3 OR L4
L6 77 SEA FILE=REGISTRY SUB=L5 SSS FUL (L1 OR L2)

(FILE 'REGISTRY' ENTERED AT 12:05:43 ON 24 JUL 2007)
ACT DAVIS524028/A

L1		STR			
L2		STR			
L3		STR			
L4		STR			
L5	(132) SEA S	SSS FUL L3	OR L4	
L6		77 SEA S	SUB=L5 SSS	FUL (L1	OR L2)

FILE 'REGISTRY' ENTERED AT 12:07:25 ON 24 JUL 2007

```
D QUE STAT
     FILE 'CAPLUS' ENTERED AT 12:07:25 ON 24 JUL 2007
L7
              5 SEA ABB=ON PLU=ON L6
                D 1-5
     FILE 'REGISTRY' ENTERED AT 12:09:19 ON 24 JUL 2007
\Gamma8
             72 SEA ABB=ON PLU=ON (660439-93-0/BI OR 660439-96-3/BI OR
                660439-99-6/BI OR 660440-22-2/BI OR 660440-23-3/BI OR
                660440-62-0/BI OR 660439-94-1/BI OR 660439-95-2/BI OR
                660439-97-4/BI OR 660439-98-5/BI OR 660440-00-6/BI OR
                660440-01-7/BI OR 660440-02-8/BI OR 660440-03-9/BI OR
                660440-05-1/BI OR 660440-07-3/BI OR 660440-12-0/BI OR
                660440-13-1/BI OR 660440-14-2/BI OR 660440-15-3/BI OR
                660440-16-4/BI OR 660440-17-5/BI OR 660440-18-6/BI OR
                660440-19-7/BI OR 660440-20-0/BI OR 660440-21-1/BI OR
                660440-24-4/BI OR 660440-25-5/BI OR 660440-26-6/BI OR
                660440-27-7/BI OR 660440-28-8/BI OR 660440-29-9/BI OR
                660440-30-2/BI OR 660440-31-3/BI OR 660440-32-4/BI OR
                660440-33-5/BI OR 660440-34-6/BI OR 660440-35-7/BI OR
                660440-36-8/BI OR 660440-37-9/BI OR 660440-38-0/BI OR
                660440-39-1/BI OR 660440-40-4/BI OR 660440-41-5/BI OR
                884347-98-2/BI OR 884347-99-3/BI OR 884348-00-9/BI OR
                915157-68-5/BI OR 915157-69-6/BI OR 915157-70-9/BI OR
                915157-71-0/BI OR 915157-72-1/BI OR 915157-73-2/BI OR
                915157-74-3/BI OR 915157-75-4/BI OR 915157-76-5/BI OR
                915157-77-6/BI OR 915157-78-7/BI OR 915157-79-8/BI OR
                915157-80-1/BI OR 915157-81-2/BI OR 915157-82-3/BI OR
                915157-83-4/BI OR 915157-84-5/BI OR 915157-85-6/BI OR
                915157-86-7/BI OR 915157-87-8/BI OR 915157-88-9/BI OR
                915157-89-0/BI OR 915157-90-3/BI OR 915157-91-4/BI OR
                915157-93-6/BI)
                D QUE
                D 1-72 REG
                D 1,5,9,18,26,27,29,35,42,58,66,72 IDE CAN
     FILE 'CAOLD' ENTERED AT 12:11:20 ON 24 JUL 2007
L9
              O SEA ABB=ON PLU=ON L6
                                    ENTERED AT 12:11:29 ON 24 JUL 2007
     FILE 'MEDLINE, BIOSIS, EMBASE'
L10
              O SEA ABB=ON PLU=ON
     FILE 'HOME' ENTERED AT 12:11:39 ON 24 JUL 2007
```

D QUE L6

	FILE 'CAPL	US, MEDLINE,	BIOSIS,	EMBASE,	WPIX,	JAPIO,	PASCAL,	DISSABS'
	ENTERED AT	15:13:07 ON	20 JUL :	2007 ·				
L15	205	SEA ABB=ON	PLU=ON	"WITHER	INGTON	J"?/AU		
L16	6337	SEA ABB=ON	PLU=ON	"ELLIOT	T R"?/	UA		
L17	12	SEA ABB=ON	PLU=ON	L15 AND	L16			
L18	24	SEA ABB=ON	PLU=ON	(L15 OR	L16) 1	(A)	LPHA4 OR	A4 OR (A
		OR ALPHA) (W)) 4)(3A)	INTEGRI	N OR (CD49? OI	R CD 49)	(5A)
		ANTIGEN OR	(CELL OR	CELLULA	R) (3A)	ADHESI	ON)	
L19	30 [°]	SEA ABB=ON	PLU=ON	L17 OR 3	L18			
L20	16	DUP REM L19	(14 DUP	LICATES I	REMOVE	D)		
		D 1-16 TBTB	ABS					

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JUL 2007 HIGHEST RN 942942-65-6 DICTIONARY FILE UPDATES: 19 JUL 2007 HIGHEST RN 942942-65-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storin of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2007 VOL 147 ISS 5 FILE LAST UPDATED: 19 Jul 2007 (20070719/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply They are available for your review at:

http://www.cas.org/infopolicy.html

FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent

assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE MEDLINE

FILE LAST UPDATED: 19 Jul 2007 (20070719/UP). FILE COVERS 1950 TO DA

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1926 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 18 July 2007 (20070718/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE EMBASE

FILE COVERS 1974 TO 20 Jul 2007 (20070720/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX

FILE LAST UPDATED: 16 JUL 2007 <20070716/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200745 <200745/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> IPC Reform backfile reclassification has been loaded to 31 May
2007. No update date (UP) has been created for the reclassified
documents, but they can be identified by 20060101/UPIC and
20061231/UPIC and 20060601/UPIC. <<<</pre>

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE JAPIO .

FILE LAST UPDATED: 4 JUL 2007

<20070704/UP>

FILE COVERS APRIL 1973 TO MARCH 29, 2007

>>> GRAPHIC IMAGES AVAILABLE <<<

FILE PASCAL

FILE LAST UPDATED: 18 JUL 2007 <20070718/UP>

FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE BASIC INDEX (/BI) FIELD <<<

FILE DISSABS

FILE COVERS 1861 TO 2 JUL 2007 (20070702/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

FILE HOME